Skip to main content
SpringerLink
Log in

Cancer therapy

Linking the microbiome to CAR-T cell responses

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

The composition of the intestinal microbiome may predict clinical outcomes of CAR-T cell therapy for lymphoma, which could inform microbiota-based intervention strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Evaluating the effects of the intestinal microbiome on outcomes of CAR-T cell therapy in patients with lymphoma.

References

  1. Peled, J. U. et al. New Engl. J. Med. 382, 822–834 (2020).

    Article  CAS  PubMed  Google Scholar 

  2. Smith, M. et al. Nat. Med. 28, 713–723 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gopalakrishnan, V. et al. Science 359, 97–103 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Routy, B. et al. Science 359, 91–97 (2018).

    Article  CAS  PubMed  Google Scholar 

  5. Stein-Thoeringer, C. K. Nat. Med. https://doi.org/10.1038/s41591-023-02234-6 (2023).

    Article  PubMed  Google Scholar 

  6. Weber, D. et al. Biol. Blood Marrow Transplant 23, 845–852 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. van Lier, Y. F. et al. Sci. Transl. Med. 12, eaaz8926 (2020).

    Article  PubMed  Google Scholar 

  8. Davar, D. et al. Science 371, 595–602 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, USA

    Zachariah DeFilipp

  2. Harvard Medical School, Boston, MA, USA

    Zachariah DeFilipp & Marcela V. Maus

  3. Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA

    Marcela V. Maus

Authors
  1. Zachariah DeFilipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcela V. Maus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcela V. Maus.

Ethics declarations

Competing interests

Z.D. receives research support from Incyte, Corp., Regimmune, Corp and Taiho Oncology, Inc. and has received consulting fees from Kadmon Corp., Omeros Corp., Incyte, Corp., MorphoSys AG, Inhibrx and PharmaBiome AG. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and University of Pennsylvania (some licensed to Novartis). M.V.M. receives Grant/Research support from: Kite Pharma. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M. holds Equity in 2SeventyBio, Century Therapeutics, Neximmune, Oncternal and TCR2. M.V.M. is on the Board of Directors of 2Seventy Bio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DeFilipp, Z., Maus, M.V. Linking the microbiome to CAR-T cell responses. Nat Med 29, 785–786 (2023). https://doi.org/10.1038/s41591-023-02272-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02272-0

  • Springer Nature America, Inc.

Search

Navigation